Contributions of host- and disease-related attributes to the outcome of patients with acute myelogenous leukemia.
- 1 April 1984
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 2 (4), 253-259
- https://doi.org/10.1200/jco.1984.2.4.253
Abstract
Three sequential trials of treatment for acute myelogenous leukemia (AML) involving 173 patients were analyzed to identify clinical and myeloblast-cell progenitor properties in culture related to outcome. The latter, including self-renewal capacity expressed as plating efficiency (PE2) and drug sensitivity, were determined for a representative group of 45 patients. Despite increasingly intensive remission induction therapy, similar response rates were achieved in the 3 trials and no increase in the duration of survival was observed. Clinical attributes at presentation by multivariate analyses were not consistently predictable of outcome. Of the blast cell attributes, only PE2 was predictive of duration of survival (P < 10-6). For patients in remission the relapse rate during the 1st yr was 0.63 compared with 0.15 in subsequent years. The percentage marrow myeloblasts at presentation, a measure of disease activity, was significantly higher for the patients having remissions lasting < 1 yr. These studies demonstrate the importance of disease-related attributes on the outcome of patients with AML.This publication has 11 references indexed in Scilit:
- Terminal deoxynucleotidyl transferase in acute myeloid leukaemiaLeukemia Research, 1983
- Acute nonlymphoblastic leukemia. Prognostic factors in adults with long-term follow-upCancer, 1982
- THE CONTRIBUTION OF BLAST CELL PROPERTIES TO OUTCOME VARIATION IN ACUTE MYELOBLASTIC-LEUKEMIA (AML)1982
- Analysis of the presenting features of adult acute leukemia: The French-American-British classificationCancer, 1981
- THE HERITABLE NATURE OF CLONAL CHARACTERISTICS IN ACUTE MYELOBLASTIC-LEUKEMIA1981
- Factors related to length of complete remission in adult acute leukemiaCancer, 1980
- Cytotoxicity of Adriamycin and Daunorubicin for Normal and Leukemia Progenitor Cells of Man2JNCI Journal of the National Cancer Institute, 1979
- Refractory Anaemia with Excess of Myeloblasts in the Bone Marrow: a Clinical Trial of Androgens in 90 PatientsBritish Journal of Haematology, 1977
- Randomized clinical trial of cystosine arabinoside and 6-thioguanine in remission induction and consolidation of adult nonlymphocytic acute leukemiaCancer, 1977
- Late intensification therapy for acute leukemia in remission. Chemotherapy and immunotherapyJAMA, 1976